# A Phase III Study of Human Papillomavirus (HPV)-16/18 Vaccine.

> **NCT02733068** · PHASE3 · COMPLETED · sponsor: **Shanghai Zerun Biotechnology Co.,Ltd** · enrollment: 12000 (actual)

## Conditions studied

- Human Papilloma Virus Infection Type 16
- Human Papilloma Virus Infection Type 18
- Cervical Intraepithelial Neoplasia

## Interventions

- **BIOLOGICAL:** HPV-16/18 vaccine
- **BIOLOGICAL:** HPV-16/18 placebo

## Key facts

- **NCT ID:** NCT02733068
- **Lead sponsor:** Shanghai Zerun Biotechnology Co.,Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-11-02
- **Primary completion:** 2019-07-30
- **Final completion:** 2020-01-16
- **Target enrollment:** 12000 (ACTUAL)
- **Last updated:** 2022-12-19

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02733068

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02733068, "A Phase III Study of Human Papillomavirus (HPV)-16/18 Vaccine.". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT02733068. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*